Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Business Wire•19/10/2026•08:00 ET
0
Key Highlights
- ➤Four IDWeek 2026 abstracts span ceftobiprole and zoliflodacin evidence generation
- ➤ZEVTERA data address contemporary U.S. isolates and pediatric treatment approaches
- ➤NUZOLVENCE data report high microbiologic eradication rates in gonorrhea patients co-infected with chlamydia
- ➤IDWeek 2026 presentations run October 21–24 in Washington, D.C.
Expert Statements
David Altarac, M.D., Chief Medical Officer at Innoviva Specialty Therapeutics
“Antimicrobial resistance remains one of the most urgent global health challenges, requiring continued innovation and rigorous evidence generation. The data we are presenting at IDWeek demonstrate the breadth of our work across infectious diseases, from evaluating ceftobiprole against contemporary clinical isolates and advancing its use in pediatric patients to sharing new insights from our zoliflodacin clinical program. Together, these findings reflect our commitment to advancing meaningful treatment options for clinicians and patients facing serious infectious diseases.”
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Presentations span ceftobiprole and zoliflodacin, highlighting post-approval evidence generation across antimicrobial-resistant and difficult-to-treat infections
Get started
Create a free account to read the full story.